Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2025 | Health maintenance for patients with CLL

Brian Koffman, MDCM (retired), CLL Society, Inc., Chula Vista, CA, provides insight into health maintenance for patients with chronic lymphocytic leukemia (CLL), emphasizing the importance of considering the patient as a whole to provide comprehensive care. Dr Koffman highlights the need for physicians to assess comorbidities and concomitant medications when selecting CLL therapies for patients, as well as ensuring that patients receive the necessary vaccinations, health checks, and psychological support to optimize their outcomes and quality of life. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

It’s a very important question and a question that’s becoming increasingly relevant in the care of CLL, and while I think every hematologist oncologist looks at their patients as a whole and tries to address all the issues in front of that patient, it’s becoming increasingly relevant in CLL as our treatments have improved. To begin with, as we all know, the CLL population tends to be elderly, you know, presenting in their early 70s, and often they already have comorbidities...

It’s a very important question and a question that’s becoming increasingly relevant in the care of CLL, and while I think every hematologist oncologist looks at their patients as a whole and tries to address all the issues in front of that patient, it’s becoming increasingly relevant in CLL as our treatments have improved. To begin with, as we all know, the CLL population tends to be elderly, you know, presenting in their early 70s, and often they already have comorbidities. But the treatments have become so excellent and generally very well tolerated that most patients are now dying with their CLL, not from their CLL. And as a result of that, understanding their comorbidities, possible drug interactions can influence not only the choice of therapy, but can also influence their care beyond just choosing what the right management of their CLL is. For example, all CLL patients, regardless of their treatment status, are immunocompromised. So being aware of that, making sure patients are up to date with their vaccinations, making sure they have appropriate prophylaxis, making sure that they’re taking proper precautions is critically important. We know that CLL patients have a much higher incidence of secondary malignancies, especially non-melanoma skin cancers. So appropriate skin checks, sunscreen, but also getting age and gender appropriate screening, colonoscopies, perhaps mammograms, PSAs, things like this, become critically important. CLL patients are at higher risk for fragility fractures in their bones. So paying attention to bone density and fall prevention is important. Cardiovascular issues are important, and some of the medications can make that worse. And of course, like any patient with a cancer diagnosis, especially a generally incurable cancer diagnosis, there’s a whole plethora of psychological issues the patients go through. So again, as good clinicians, we want to be aware of those things and address all these issues as they’re rising in importance and sometimes are more important to the patient than what their actual treatment is.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Consultancy: Abbvie, BeOnc, BMEA, BMS, JNJ, Lilly; Honoraria: AstraZeneca, BMS, GenMab, Invyvid; Equity ownership: Abbvie, AstraZeneca, BeOne, BMEA, BMS, Invyvid, JNJ, Merck, Nurix, Pfizer, VINC.